Salvage therapy at biochemical recurrence of prostate cancer

Nature Reviews Urology, Published online: 12 February 2020; doi:10.1038/s41585-020-0290-3No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the interval to biochemical failure.

Source: Nature Reviews Urology - February 11, 2020 Category: Urology & Nephrology Authors: Nicholas G. Zaorsky Amar U. Kishan Source Type: research